A rare case of NXP-2 positive dermatomyositis

Nariman Khan, Zehra Hasan Kazmi, Rahaf Alkhateb

Abstract


Dermatomyositis is an idiopathic inflammatory myopathy with variable cutaneous manifestations. Several autoantibodies each with distinct clinical phenotypes are associated with the disease. Here we present the case of a 36-year-old Laotian woman with hypothyroidism who presented with severe proximal and distal muscle weakness, dysphagia, diffuse rash, and anasarca that was diagnosed with NXP-2 (nuclear matrix protein 2) antibody positive dermatomyositis. The patient’s hospitalization was complicated by disease resistant to conventional therapy.


Keywords


rheumatology; hypothyroidism; dermatomyositis; NXP-2

Full Text:

PDF

References


Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol 2017; 8:992.

Hu T, Vinik O. Dermatomyositis and malignancy. Can Fam Physician 2019; 65(6):409-411.

Myositis Antibodies. Myositis Support and Understanding, [https://understandingmyositis.org/myositis-antibody-testing available at 03.28.2021]

Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear Matrix Protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 2017; 69(11):1771-1776.

Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36(11):2547-2551.

Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Cutaneous and systemic findings associated with Nuclear Matrix Protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) 2017; 69(12):1909-1914.

Dermatomyositis. NORD (National Organization for Rare Disorders), [https://rarediseases.org/rare-diseases/dermatomyositis Available at 03.28.2021]

Ruhlman D, Otten C, Collela C. Dermatomyositis. J Nurse Pract 2014; 10(9):674-681.

Miller ML. Initial treatment of dermatomyositis and polymyositis in adults. In UpToDate, Ramirez Curtis, M (Ed), UpToDate, Waltham, MA, 2021.

Miller ML. Treatment of recurrent and resistant dermatomyositis and polymyositis in adults. In UpToDate, Ramirez Curtis, M (Ed), UpToDate, Waltham, MA, 2021.

Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: An open label pilot study of 10 patients. Arthritis Rheumatol 2020; Epub ahead of print. PMID: 33258553. doi: 10.1002/art.41602.

Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J 2006; 82(969):417-424.




DOI: http://dx.doi.org/10.22551/2020.29.0704.10176

Copyright (c) 2021 Nariman Khan, Zehra Hasan Kazmi, Rahaf Alkhateb

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975